17.7% decline in incidence rate of TB in India, from 237 per lakh population in 2015 to 195 per lakh population in 2023
New Delhi : Union Minister of State for Health and Family Welfare, Smt. Anupriya Patel inaugurated the India Innovation Summit – Pioneering Solutions to End TB, at Bharat Mandapam Convention Centre, here today. The Summit is being organized jointly by the Department of Health Research-Indian Council of Medical Research (DHR-ICMR) and the Central TB Division (CTD), Ministry of Health & Family Welfare (MoHFW). The summit aims to accelerate India’s progress towards TB elimination by 2025.
Addressing the gathering, Smt. Anupriya Patel highlighted India’s remarkable progress in TB control and the pivotal role of innovation in this mission. She stated that “under the pathbreaking leadership of our Hon’ble Prime Minister, Shri Narendra Modi, India’s public health landscape has seen a remarkable transformation over the past decade and many of you have played a critical role in ensuring innovations and quality healthcare services reach the last mile.”
Highlighting the achievements of the National TB Elimination Program (NTEP), Smt. Patel stated that “the Program is steadily progressing towards the goal of eliminating TB by 2025. The number of missing cases has been reduced from 15 lakh in 2015 to 2.5 lakhs in 2023. The programme was able to notify 25.5 lakh TB and 26.07 lakh cases in 2023 and 2024-the highest ever.”
Citing the WHO’s Global TB Report 2024, Smt. Patel stated that “the incidence rate of TB in India has shown a 17.7% decline from 237 per lakh population in 2015 to 195 per lakh population in 2023. TB deaths have reduced by 21.4% from 28 per lakh population in 2015 to 22 per lakh population in 2023.” She also added that “TB treatment coverage in India increased by 32% in last eight years from 53% in 2015 to 85% in 2023.”
The Union Minister of State also highlighted the new initiatives under NTEP. She stated that “a shorter and safer oral Bedaquiline-containing drug resistant TB treatment regimen has been rolled out across all State/ UTs that has improved treatment success rates of drug-resistant TB patients from 68% in 2020 to 75% in 2022. A more efficacious treatment regimen, mBPaL (Bedaquiline, Pretomanid, Linezolid (300mg) has also been introduced for drug-resistant TB which is 80% more efficacious for multidrug-resistant tuberculosis (MDR TB) and will reduce treatment duration to 6 months.”
She also highlighted the Energy Dense Nutritional Support (EDNS), offered to under-nourished TB patients during the first 2 months of their treatment along with drugs. Talking about the Ni-kshay Mitra Initiative that was launched with the objectives to provide additional support to TB patients in order to improve treatment outcomes, augment community involvement and leverage Corporate Social Responsibility (CSR) activities, Smt. Patel stated that “this initiative was launched to bring together people from all backgrounds into a ‘Jan Andolan’ and escalate the progress toward TB elimination.” She further added that “the Government has doubled the financial assistance under Ni-kshay Poshan Yojana (NPY) for nutritional support to TB patients from Rs 500/per month/per patient to Rs 1,000 per month per patient effective from 1st November 2024 while the Ni-kshay Mitra Initiative has also been expanded wherein food baskets to TB patients and their household contacts are being provided.